Cytokinetics CYTK Royalty — Fair Value Of Royalty

Similar metrics at other companies

INCYRoyalty-bearing product other than GITR, OX40 and one undisclosed target — Royalty payments on future global net sales (as a percent)

12%—

VICRRoyalty — Revenue

$14.97M+39.1%

BBIORoyalty Revenue — Revenue

$1.62M—

AXSMRoyalty — Revenue

$4.07M+269%

IONSRoyalty — Revenue

$58.32M-9.1%

VICRRoyalties — Revenue

$14.97M+39.1%

Questions, answered.

What does royalty — fair value of royalty mean?

The estimated current worth of all future royalty payments the company expects to receive from its licensed technology.

How do you interpret royalty — fair value of royalty?

An increase suggests higher expected future cash flows from licensed products or improved market performance of those products, while a decrease may indicate lower sales projections or increased risk in the underlying royalty agreements.

How does royalty — fair value of royalty compare across companies?

Comparable to the valuation of intangible assets or royalty-based revenue streams found in other biotechnology and pharmaceutical companies with significant out-licensing activities.